key: cord-0315411-70s04wty
authors: Kojima, N.; Roshani, A.; Brobeck, M.; Baca, A.; Klausner, J. D.
title: Incidence of Severe Acute Respiratory Syndrome Coronavirus-2 infection among previously infected or vaccinated employees
date: 2021-07-07
journal: nan
DOI: 10.1101/2021.07.03.21259976
sha: 753fc15e62226073fa23cfe5fca52ffd9ce05927
doc_id: 315411
cord_uid: 70s04wty

Introduction: The protective effect of previous infection versus vaccination is poorly studied. Among a clinical laboratory that has been conducting routine workforce screening since the beginning of the pandemic, we aimed to assess the relative risk of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection among individuals who were SARS-CoV-2 naive, previously infected, or vaccinated. Methods: Using an electronic laboratory information system, employees were divided into three groups: (1) SARS-CoV-2 naive and unvaccinated, (2) previous SARS-CoV-2 infection, and (3) vaccinated. Person-days were measured from the date of the employee first test and truncated at the end of the observation period. SARS-CoV-2 infection was defined as two positive SARS-CoV-2 PCR tests in a 30-day period. Individuals with fewer than 14 days of follow up were excluded. Incidence estimates and the 95% confidence intervals were calculated using the Poisson Exact equation. The incidence rate ratio (IRR) was used as a measure of association between groups. Analyses were performed on StataSE (StataCorp, College Station, TX). Results: We identified 4313, 254 and 739 employee records for groups 1, 2, and 3, respectively. The median age of employees was 29.0 years (interquartile range: 23.6, 39.9). During the observation period, 254, 0, and 4 infections were identified among groups 1, 2, and 3, respectively. Group 1 had an incidence of 25.9 per 100 person-years (95% CI: 22.8-29.3). Group 2 had an incidence of 0 per 100 person-years (95% CI: 0-5.0). Group 3 had an incidence of 1.6 per 100 person-years (95% CI: 0.04-4.2). The IRR of reinfection among those with previous infection compared to SARS-CoV-2 naive was 0 (95% CI: 0-0.19). The IRR of those vaccinated compared to SARS-CoV-2 naive was 0.06 (95% CI: 0.02-0.16). The IRR of those vaccinated compared to prior SARS-CoV-2 was 0 (95% CI: 0-4.98). Conclusion: Previous SARS-CoV-2 infection and vaccination for SARS-CoV-2 were associated with decreased risk for infection or re-infection with SARS-CoV-2 in a routinely screened workforce. The was no difference in the infection incidence between vaccinated individuals and individuals with previous infection. Further research is needed to determine whether our results are consistent with the emergence of new SARS-CoV-2 variants.

Introduction: The protective effect of previous infection versus vaccination is poorly 26 studied. Among a clinical laboratory that has been conducting routine workforce 27 screening since the beginning of the pandemic, we aimed to assess the relative risk of 28

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection among 29 individuals who were SARS-CoV-2 naïve, previously infected, or vaccinated. Individuals with fewer than 14 days of follow up were excluded. Incidence estimates and 36 the 95% confidence intervals were calculated using the Poisson Exact equation. The 37

incidence rate ratio (IRR) was used as a measure of association between groups. 38

Analyses were performed on StataSE (StataCorp, College Station, TX). 39

We identified 4313, 254 and 739 employee records for groups 1, 2, and 3, 40 respectively. The median age of employees was 29.0 years (interquartile range: 23.6, 41 39.9). During the observation period, 254, 0, and 4 infections were identified among 42 groups 1, 2, and 3, respectively. Group 1 had an incidence of 25.9 per 100 person-43 years (95% CI: 22.8-29.3). Group 2 had an incidence of 0 per 100 person-years (95% 44 CI: 0-5.0). Group 3 had an incidence of 1.6 per 100 person-years (95% CI: 0.04-4.2). 45

The IRR of reinfection among those with previous infection compared to naïve was 0 (95% CI: 0-0.19). The IRR of those vaccinated compared to SARS-CoV-2 47 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.03.21259976 doi: medRxiv preprint 3 naïve was 0.06 (95% CI: 0.02-0.16). The IRR of those vaccinated compared to prior 48 SARS-CoV-2 was 0 (95% CI: 0-4.98). CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021.

Prior reports have found lower rates of Severe Acute Respiratory Syndrome 59

Coronavirus-2 (SARS-CoV-2) infections among those with prior infection or 60 vaccination. 1, 2 Although an association between vaccination and reduction of SARS-61

CoV-2 incidence has been well described, how the incidence among individuals with 62 previous infection compares to vaccinated individuals remains unclear. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.03.21259976 doi: medRxiv preprint 5 Person-days were measured from the first test date to last test date up to December 80 15 th , 2020 for groups 1 and 2 and up to July 1, 2021 for group 3. We defined SARS-81

CoV-2 infection as two positive PCR tests in a 30-day period. Individuals with fewer 82 than 14 days of follow up were excluded. Incidence in 100 person-years with 95% 83 confidence intervals (95% CIs) was calculated with the Poisson Exact equation. The 84

incidence rate ratio (IRR), the ratio of confirmed COVID-19 cases per 100 person-years 85 of follow up with 95% CIs, was used as a measure of association between groups. 86

Analyses were performed on StataSE (StataCorp, College Station, TX). The study of 87 de-identified electronic medical record data was determined by the Advarra institutional 88 review board (Pro00054560) to be exempt from review. 89 90

We identified 4313, 254 and 739 employee records for the naïve and unvaccinated 92 group (Group 1), the previously infected and unvaccinated group (Group 2) and the 93 vaccinated without previous infection group (Group 3), respectively. The median age of 94 employees was 29.0 years (interquartile range: 23.6, 39.9). During the observation 95 period, 254, 0, and 4 SARS-CoV-2 incident infections were identified among Groups 1, 96 2, and 3, respectively. (Table) . 97

The naïve, unvaccinated group had a SARS-CoV-2 incidence of 25.9 per 100 person-99 years (95% CI: 22.8-29.3). The previously infected, unvaccinated group had an 100 incidence of 0 per 100 person-years (95% CI: 0-5.0). The vaccinated group had an 101 incidence of 1.6 per 100 person-years (95% CI: 0.04-4.2). The IRR of reinfection among 102 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.03.21259976 doi: medRxiv preprint 6 those with previous infection compared to those SARS-CoV-2 naïve was 0 (95% CI: 0-103 0.19). The IRR of those vaccinated compared to those SARS-CoV-2 naïve was 0.06 104 (95% CI: 0.02-0.16). The IRR of those vaccinated compared to those previously SARS-105

CoV-2 infected was 0 (95% CI: 0-4.98). CoV-2 infection and those who were vaccinated had lower rates of SARS-CoV-2 124 infection compared to those who were SARS-CoV-2 naïve and unvaccinated. 5 125 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.03.21259976 doi: medRxiv preprint After vaccination or natural infection, many mechanisms of immunity exist including 127 humoral and cellular immunity. 6-8 It is known that SARS-CoV-2 infection induces specific 128 and durable T cell immunity against multiple SARS-CoV-2 spike (S) protein targets (or program. In addition, because allocation to each exposure group was not random, there 138 might be differences between groups in the risk of repeat exposure over time. The study 139 was strengthened by the high incidence among those naïve and unvaccinated, the large 140 sample size and large number of person-years of follow up in each group. 141 142

We found a strong association between prior SARS-CoV-2 infection and vaccination for 144 SARS-CoV-2 with either BNT162b2 or mRNA-1273 and the reduced incidence of 145 SARS-CoV-2 when compared to those naïve and unvaccinated to SARS-CoV-2. The 146 was no difference in the incidence of SARS-CoV-2 between individuals who were 147 vaccinated and individuals with prior SARS-CoV-2 infection. Combined with prior 148 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. The staff at Curative Inc. 162 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.03.21259976 doi: medRxiv preprint

Re-infection with SARS-CoV-2 in 164

BNT162b2 mRNA Covid-19 Vaccine in a 167

Nationwide Mass Vaccination Setting

Self-Collected Oral Fluid and Nasal Swab 170

Specimens Demonstrate Comparable Sensitivity to Clinician-Collected Nasopharyngeal 171

Swab Specimens for the Detection of SARS-CoV-2

An observational cohort study on 174 the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare 175 workers by antibody and vaccination status

Necessity of COVID-19 vaccination 178 in previously infected individuals

Covid-19: Do many people have pre-existing immunity? Bmj

SARS-CoV-2-specific T cell immunity 182 in cases of COVID-19 and SARS, and uninfected controls

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021.